Skip to main content

Cancer metabolism

Guest Editors:
Elavarasan Subramani: The University of Texas M.D. Anderson Cancer Center, United States
Marija Trajkovic-Arsic: German Cancer Consortium, Germany

BMC Cancer has published this Collection on metabolism rewiring in cancer.


Meet the Guest Editors

Back to top

Elavarasan Subramani: The University of Texas M.D. Anderson Cancer Center, United States

Dr. Subramani is a research investigator at the Department of Cancer Systems Imaging, The UT M.D. Anderson Cancer Center. He has considerable experience in metabolomics, cell, and molecular biological approaches, developing in vitro and in vivo biomarker development and drug discovery models, and defining cancer pathophysiology. He has developed and mechanistically validated robust non-invasive translatable biomarkers that can be used to identify oncogenic events associated with low-grade gliomas and that can be used to monitor response to a broad range of therapies.

Marija Trajkovic-Arsic: German Cancer Consortium, Germany

Dr. Trajkovic-Arsic obtained her Ph.D. in Endocrinology in 2008. Since 2010 she has been active in cancer research focusing on pancreatic ductal adenocarcinoma (PDAC). She is dedicated to deciphering pancreatic cancer's metabolic dependencies and further developing imaging-based approaches for reliable non-invasive detection of PDACs metabolism and its metabolic vulnerabilities. She is mostly known for her research on preclinical mouse models of PDAC and imaging technologies used for addressing PDACs heterogeneity, microenvironment complexity, metabolic activity, and therapy development and evaluation. 

About the collection

BMC Cancer has published this Collection on metabolism rewiring in cancer.

The first observations on metabolic alterations in cancer were made nearly a century ago by Otto Warburg, who discovered the metabolic differences between lactate production of cancer cells and non-malignant tissues. It is now well known that metabolic perturbations are a hallmark of cancer, which allows cancer cells to sustain their uncontrolled proliferation even in a frequently nutrient-poor environment. In the past decade, the field of cancer metabolism has become a topic of renewed interest, unrevealing the impact of metabolic rewiring in the cancer-microenvironment crosstalk and the onset of therapeutic resistance and metastasis.

In recognition of this important field, BMC Cancer has published this Collection which encouraged submissions including but not limited to those addressing:

• Genetic alterations involved in the metabolic reprogramming 

• Metabolic alterations within the microenvironment 

• Therapeutic approaches targeting cancer metabolism at the cellular or organismal levels 

• Metabolites as tumor biomarkers

• Tumor metabolism as a diagnostic tool

• Tumor metabolism and therapy response imaging technologies

• Redox homeostasis in cancer metabolism

• Cancer metabolomics and multi-omics data integration

• Sex-specific metabolic alterations in cancers

• Improving in vitro cancer metabolism studies (new media formulations/conditions)

Image credit: © nobeastsofierce / Stock.adobe.com

  1. Hepatocellular carcinoma (HCC), a prevalent primary malignant tumor, is notorious for its high mortality rate. Despite advancements in HCC treatment, patient outcomes remain suboptimal. This study endeavors to...

    Authors: Yan Dong, Xinyi Chen, Shen Yang, Yilong Fu, Liangyu Wang, Xueping Gao, Di Chen and Lixia Xu
    Citation: BMC Cancer 2024 24:1112
    Content type: Research Published on:

  2. Metabolic dysregulation is recognized as a significant hallmark of cancer progression. Although numerous studies have linked specific metabolic pathways to cancer incidence, the causal relationship between blo...

    Authors: Gujie Wu, Jun Liu, Haochun Shi, Binyang Pan, Min Li, Xiaolin Wang, Yao Li, Lin Cheng, Weigang Guo and Yiwei Huang
    Citation: BMC Cancer 2024 24:854
    Content type: Research Published on:

  3. Pancreatic ductal adenocarcinoma (PDAC) is a ‘difficult-to-treat’ entity. To forecast its prognosis, we introduced a new biomarker, SARIFA (stroma areactive invasion front areas), which are areas at the tumour...

    Authors: Przemyslaw Grochowski, Bianca Grosser, Florian Sommer, Andreas Probst, Johanna Waidhauser, Gerhard Schenkirsch, Nic G. Reitsam and Bruno Märkl
    Citation: BMC Cancer 2024 24:768
    Content type: Research Published on:

  4. A growing number of expression quantitative trait loci (eQTLs) have been found to be linked with tumorigenesis. In this article, we employed integrated Mendelian randomization (MR) analyses to identify novel s...

    Authors: Qiming Wang, Shaopeng Chen, Gang Wang, Tielong Zhang and Yulong Gao
    Citation: BMC Cancer 2024 24:739
    Content type: Research Published on:

  5. The Naples Prognostic Score (NPS), integrating inflammatory and nutritional biomarkers, has been reported to be associated with the prognosis of various malignancies, but there is no report on intrahepatic cho...

    Authors: Cheng-Fei Du, Zhen-Yu Gao, Zhu-Ding Xu, Zheng-Kang Fang, Zi-Chen Yu, Zhe-Jin Shi, Kai-Di Wang, Wen-Feng Lu, Xiao-Kun Huang, Lei Jin, Tian-Wei Fu, Guo-Liang Shen, Jun-Wei Liu, Cheng-Wu Zhang, Dong-Sheng Huang and Lei Liang
    Citation: BMC Cancer 2024 24:727
    Content type: Research Published on:

  6. Our previous studies have indicated that mRNA and protein levels of PPIH are significantly upregulated in Hepatocellular Carcinoma (LIHC) and could act as predictive biomarkers for patients with LIHC. Nonetheless...

    Authors: Jun Ye, Jianchao Ying, Haixia Chen, Zhiping Wu, Chaolin Huang, Chuan Zhang, Zhitao Chen and Haini Chen
    Citation: BMC Cancer 2024 24:681
    Content type: Research Published on:

  7. Understanding the metabolic changes in colorectal cancer (CRC) and exploring potential diagnostic biomarkers is crucial for elucidating its pathogenesis and reducing mortality. Cancer cells are typically deriv...

    Authors: Xuancheng Wang, Xuan Guan, Ying Tong, Yunxiao Liang, Zongsheng Huang, Mingsen Wen, Jichu Luo, Hongwei Chen, Shanyi Yang, Zhiyong She, Zhijuan Wei, Yun Zhou, Yali Qi, Pingchuan Zhu, Yanying Nong and Qisong Zhang
    Citation: BMC Cancer 2024 24:644
    Content type: Research Published on:

  9. Meningiomas are among the most common primary tumors of the central nervous system. Previous research into the meningioma histological appearance, genetic markers, transcriptome and epigenetic landscape has re...

    Authors: D. Orešković, A. Madero Pohlen, I. Cvitković, J.F. Alen, M. Raguž, A. Álvarez-Sala de la Cuadra, G.J. Bazarra Castro, Z. Bušić, I. Konstantinović, V. Ledenko, C. Martínez Macho, D. Müller, M. Žarak, N. Jovanov-Milosevic, D. Chudy and T. Marinović
    Citation: BMC Cancer 2024 24:488
    Content type: Research Published on:

  10. Clear cell renal cell carcinoma (ccRCC) is the prevailing histological subtype of renal cell carcinoma and has unique metabolic reprogramming during its occurrence and development. Cell senescence is one of th...

    Authors: Lijie Zhou, Youmiao Zeng, Yuanhao Liu, Kaixuan Du, Yongbo Luo, Yiheng Dai, Wenbang Pan, Lailai Zhang, Lei Zhang, Fengyan Tian and Chaohui Gu
    Citation: BMC Cancer 2024 24:451
    Content type: Research Published on:

  11. T cell immunoglobulin and mucin-domain containing-3 (TIM-3) is a cell surface molecule that was first discovered on T cells. However, recent studies revealed that it is also highly expressed in acute myeloid l...

    Authors: Hooriyeh Shapourian, Mustafa Ghanadian, Nahid Eskandari, Abolfazl Shokouhi, Gülderen Yanikkaya Demirel, Alexandr V. Bazhin and Mazdak Ganjalikhani-Hakemi
    Citation: BMC Cancer 2024 24:125
    Content type: Research Published on:

  12. Prostate cancer is a common solid tumor that affects a significant number of men worldwide. Conventional androgen deprivation therapy (ADT) increases the risk of developing castration-resistant prostate cancer...

    Authors: Xingchen Dai, Xinyi Shi, Mingxiu Luo, Pu Li and Yujing Gao
    Citation: BMC Cancer 2023 23:1241
    Content type: Research Published on:

  14. Glioblastoma patients commonly develop resistance to temozolomide chemotherapy. Hypoxia, which supports chemotherapy resistance, favors the expansion of glioblastoma stem cells (GSC), contributing to tumor rel...

    Authors: Nadia Sousa, Carsten Geiß, Laura Bindila, Ingo Lieberwirth, Ella Kim and Anne Régnier-Vigouroux
    Citation: BMC Cancer 2023 23:762
    Content type: Research Published on:

  15. Altered cellular metabolism has long been recognized as a hallmark of cancer. Oncogenic signaling cascades induce metabolic rewiring that further supports tumorigenesis, therapy resistance and metastasis. In v...

    Authors: Marija Trajkovic-Arsic and Elavarasan Subramani
    Citation: BMC Cancer 2023 23:484
    Content type: Editorial Published on:

Submission Guidelines

Back to top

This Collection welcomes the submission of Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Cancer metabolism" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.